Doxorubicin pathways
- 1 July 2011
- journal article
- pharmgkb summary
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 21 (7), 440-446
- https://doi.org/10.1097/fpc.0b013e32833ffb56
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical TrialClinical Cancer Research, 2009
- Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancerInternational Journal of Cancer, 2009
- Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese populationPharmacogenetics and Genomics, 2009
- Pharmacogenetics of Human Carbonyl Reductase 1 (CBR1) in Livers from Black and White DonorsDrug Metabolism and Disposition, 2008
- Topoisomerase levels determine chemotherapy response in vitro and in vivoProceedings of the National Academy of Sciences of the United States of America, 2008
- Function-Altering SNPs in the Human Multidrug Transporter Gene ABCB1 Identified Using a Saccharomyces-Based AssayPLoS Genetics, 2007
- Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfallsCell Biology and Toxicology, 2006
- Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitutionJournal of Human Genetics, 2001
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- P-glycoprotein—A mediator of multidrug resistance in tumour cellsEuropean Journal of Cancer, 1996